Alpha Synuclein S129A Mutant Pre-formed Fibrils
Produktgrößen
100 ug
£632,00
SPR-506-100UG
2 x 100 ug
£936,00
SPR-506-2X100UG
5 x 100 ug
£1776,00
SPR-506-5X100UG
Über dieses Produkt
- SKU:
- SPR-506
- Zusätzliche Namen:
- Alpha-synuclein, Alpha synuclein, Non-A beta component of AD amyloid, Non-A4 component of amyloid precursor, NACP, SNCA, PARK1, SYN, PD1, PARK4, Synuclein Alpha, Parkinson's disease familial 1 Protein, Alpha Synuclein S129A, Asyn, Alpha Synuclein PFFs
- Anwendung:
- Cell-based/Functional Assay, Western Blot
- Buffer:
- 1X PBS pH7.4
- CE/IVD:
- RUO
- Konzentration:
- 2 mg/ml
- Weitere Details:
- Alpha-synuclein (A Alpha-synuclein), a neuronal protein encoded by the SNCA gene, plays a central role in synaptic function and is a key driver of pathology in Parkinson's disease and related synucleinopathies. Phosphorylation at serine 129 (S129) is a prominent post-translational modification observed in aggregated A Alpha-synuclein within Lewy bodies. The S129A mutation replaces serine with alanine, effectively blocking phosphorylation at this site and enabling researchers to study its functional impact. Pre-formed fibrils (PFFs) generated from S129A mutant monomers exhibit distinct structural and biochemical properties compared to wild-type fibrils. These phosphorylation-null fibrils allow for precise investigation into the role of S129 phosphorylation in aggregation, seeding, and neurotoxicity. In cellular and animal models, S129A PFFs induce A Alpha-synuclein pathology while bypassing phosphorylation-dependent signaling pathways, offering insights into alternative mechanisms of disease progression. S129A mutant PFFs are instrumental in dissecting the molecular basis of A Alpha-synuclein aggregation, intercellular transmission, and neuronal dysfunction. Their use supports the development of targeted therapies aimed at modulating post-translational modifications, inhibiting fibril formation, and enhancing protein clearance. By modeling a phosphorylation-resistant form of A Alpha-synuclein, S129A mutant PFFs provide a powerful platform for advancing neurodegenerative disease research and accelerating therapeutic discovery for Parkinson's disease and other A Alpha-synucleinopathies.
- Immunogen:
- Alpha Synuclein S129A PFFs
- Molekulargewicht:
- 14.44 kDa
- Reinheit:
- >95%
- Aufreinigung:
- Ion Exchange
- Sequenz:
- MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGKNEEGAPQEGILEDMPVDPDNEAYEMPAEEGYQDYEPEA
- Versandbedingungen:
- Dry Ice
- Lagerbedingungen:
- -70[o]C
- Hersteller:
- StressMarq Biosciences
- Typ:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Recombinant Proteins
- Datenblatt des Herstellers:https://www.stressmarq.com/products/protein/alpha-synuclein-s129a-mutant-pre-formed-fibrils-spr-506/